| Brown MJ[17]
|
2011 |
Multicenter double-blind, randomised, parallel-group, superiority trial |
1247 participants, 315 patients were randomlyassigned to amlodipine 10 mg, 315 patientswere randomly assigned to aliskiren300 mg, and 617 to aliskiren/amlodipine300/10 mg, aged>18 years. |
Combination therapy:aliskiren/amlodipine 150 mg/5 mg, 300 mg/10 mg, once daily. Monotherapy: amlodipine 5 mg, or 10 mg, oncedaily. Aliskiren 150 mg, or 300 mg,once daily. |
BP reduction, rate of adverse events in total participants, laboratory evaluations. |
8 weeks |
188 |
Low risk |
| Weinberger MH[14]
|
2011 |
Prospective, multicenter, randomized, double-blind, parallel-group |
443 participants, 223 patients were randomlyassigned to amlodipine, and 220 to aliskirenplus amlodipine, aged>18 years. |
Combination therapy: aliskiren/amlodipine 300 mg/10 mg, oncedaily. Monotherapy: amlodipine10 mg, once daily. |
BP reduction, rate of adverse events in total participants. |
8 weeks |
33 |
Moderate risk |
| Pfeiffer D[18]
|
2012 |
Multicenter, randomized, double-blind, parallel-group |
847 participants, 283 patients were randomlyassigned to amlodipine, and 279 to aliskiren/amlodipine 300/10 mg, 285 to aliskiren/amlodipine 150/10 mg, aged>18 years. |
Combination therapy: aliskiren/amlodipine 300 mg/10 mg,150/10 mg once daily. Monotherapy:amlodipine 10 mg once daily. |
BP reduction, rate of adverse events in total participants, laboratory evaluations. |
8 weeks |
61 |
Low risk |
| Drummond W[13]
|
2007 |
Multicenter, randomized, double-blind, active-controlled, parallel-group study |
545 participants, 180 patients were randomlyassigned to amlodipine 5 mg, 178 patientswere randomly assigned to amlodipine10 mg, and 187 to aliskiren plus amlodipine,aged>18 years. |
Combination therapy:aliskiren/amlodipine 150 mg/5 mg, oncedaily. Monotherapy: amlodipine5 mg, or 10 mg, once daily. |
BP reduction, rate of adverse events in total participants. |
6 weeks |
22 |
Moderate risk |
| Glorioso N[16]
|
2012 |
Multicenter, randomized, double-blind, parallel-group multicenter study |
820 participants, 260 patients were randomlyassigned to aliskiren 300 mg, 277 patients wererandomly assigned to aliskiren/amlodipine300/5 mg, and 283 to aliskiren/amlodipine300/10 mg, aged>18 years. |
Combination therapy:aliskiren/amlodipine 300 mg/5 mg,300/10 mg, once daily. Monotherapy:aliskiren 10 mg, once daily. |
BP reduction, rate of adverse events in total participants, laboratory evaluations. |
8 weeks |
41 |
Low risk |
| Braun-DullaeusRC [15]
|
2012 |
Multicentre, randomized, double-blind study |
485 participants, 241 patients were randomlyassigned to amlodipine 10 mg, and 244 toaliskiren/amlodipine 300/10 mg,aged>18 years. |
Combination therapy: aliskiren/amlodipine 300 mg/10 mg, oncedaily. Monotherapy: amlodipine10 mg, once daily. |
BP reduction, rate of adverse events in total participants, laboratory evaluations. |
7 weeks |
52 |
Moderate risk |
| LittlejohnTW[19]
|
2012 |
Multicentre, randomized, double-blind, placebo-controlled |
1687 participants, 198 participants wererandomly assigned to placebo; 195 participants wererandomly assigned to aliskiren 150 mg, 203participants to aliskiren 300 mg; 185 participantswere randomly assigned to amlodipine 5 mgand 181 to amlodipine 10 mg; 181 participantswere randomly assigned to aliskiren/amlodipine150/5 mg, 183 participants to aliskiren/amlodipine150/10 mg, 178 participants to aliskiren/amlodipine300/5 mg, and 183 participants to aliskiren/amlodipine300/10 mg, aged>18 years. |
Combination therapy: aliskiren/amlodipine 300/5 mg, 300/10 mg,150/5 mg, 150/10 mg once daily.Monotherapy: amlodipine 5 mg,10 mg; aliskiren 150 mg,300 mg once daily. |
BP reduction, rate of adverse events in total participants, laboratory evaluations. |
8 weeks |
149 |
Low risk |
